Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of mecapegfilgrastim for neutrophil recovery after chemotherapy in AML
ChiCTR2100050080Phase 2Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mecapegfilgrastim in acute myeloid leukemia (AML), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Neutrophil recovery time. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100050080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050080.